Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of Levofloxacin versus Ceftriaxone Sodium and Erythromycin Followed by Clarithromycin and Amoxicillin- Clavulanate in the Treatment of Serious Community-Acquired Pneumonia in Adults
Abstract
This randomized, multicenter, phase IV, comparative trial, which was designed to show equivalence, compared the efficacy of levofloxacin with that of a β-lactam-macrolide combination in the treatment of 269 seriously ill patients with community-acquired pneumonia. Patients were randomly assigned to 1 of 2 treatment arms: (1) levofloxacin, 500 mg intravenously, followed by oral administration, every 24 h for 7–14 days, or (2) ceftriaxone sodium, 1–2 g intravenously or intramuscularly every 24 h, with erythromycin, 500–1000 mg intravenously every 6 h, and then switched to amoxicillin-clavulanate, 875 mg orally twice daily, with clarithromycin, 500 mg orally twice daily for 7–14 days. Among patients evaluable for clinical efficacy, 89.5% of levofloxacin-treated patients (85 of 95 patients) and 83.1% of comparator-treated patients (74 of 89 patients) achieved clinical success (a cure or an improved condition). Both levofloxacin and the comparator were safe and well tolerated, with gastrointestinal disorders being the most common adverse event in both groups. Levofloxacin was as efficacious as theβ-lactam-macrolide combination in the treatment of seriously ill patients with community-acquired pneumonia.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 269 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.